WebSurgery, chemotherapy, radiotherapy and immunotherapy are currently the main options for cancer treatment. However, ... CAFs-derived IL-6 could upregulate CXCR7 in esophageal squamous cell carcinoma and promote resistance to cisplatin via the JAK/STAT3 pathway (Qiao et al., 2024). WebJun 5, 2024 · This study aimed to investigate whether resistance to cisplatin (CDDP), the standard treatment for OC, is due to the remodeling of the tumor immune …
Cancers Free Full-Text Immunotherapy for Urothelial …
WebJun 7, 2011 · Several meta-analyses have demonstrated that neoadjuvant cisplatin-containing combination chemotherapy improves overall survival by 5%–7% at 5 years, irrespective of the type of definitive treatment used, whereas neither randomized trials nor meta-analyses have provided sufficient data to support the routine use of adjuvant … WebMay 12, 2024 · report findings from cohort 2 of EV-201, assessing enfortumab vedotin in the post-immunotherapy setting in cisplatin-ineligible patients. The primary endpoint was … luz de teto palio
Cisplatin resistance driver claspin is a target for …
WebCisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, lung and cervical cancer. It may also be used to treat other cancers. It is best to read this information with our general information about chemotherapy and the … WebSep 20, 2024 · Cisplatin / pharmacology Dendritic Cells / drug effects Galectin 3 / drug effects Humans Interleukin-10 / metabolism Interleukin-6 / metabolism Lung Neoplasms / drug therapy* Lung Neoplasms / immunology Macrophage-1 Antigen / drug effects Macrophages / drug effects* Mice Polysaccharides / pharmacology* Quality of Life T … WebApr 15, 2024 · A 64-year-old man exhibited lack of efficacy during treatment with pirarubicin, gemcitabine and cisplatin for metastatic, high-grade non-muscle invasive bladder … luz diamonds